Analysts Set IceCure Medical Ltd. (NASDAQ:ICCM) PT at $2.39

IceCure Medical Ltd. (NASDAQ:ICCM) has been given an average recommendation of “Moderate Buy” by the five brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $2.3850.

A number of research firms have weighed in on ICCM. Wall Street Zen lowered IceCure Medical from a “hold” rating to a “sell” rating in a report on Saturday, July 12th. Zacks Research lowered IceCure Medical from a “strong-buy” rating to a “hold” rating in a report on Friday, August 15th. Brookline Capital Management restated a “buy” rating on shares of IceCure Medical in a report on Wednesday, August 13th. Loop Capital set a $2.77 target price on IceCure Medical in a report on Wednesday, August 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a report on Saturday, September 27th.

IceCure Medical Stock Down 2.6%

Shares of NASDAQ:ICCM opened at $0.96 on Friday. IceCure Medical has a 52-week low of $0.48 and a 52-week high of $1.66. The stock has a market cap of $66.23 million, a P/E ratio of -6.03 and a beta of 0.31. The business’s 50 day moving average is $0.98 and its 200 day moving average is $1.04. The company has a quick ratio of 0.88, a current ratio of 1.18 and a debt-to-equity ratio of 0.02.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings data on Wednesday, August 13th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.12. IceCure Medical had a negative return on equity of 136.96% and a negative net margin of 317.62%.The company had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $0.90 million. Sell-side analysts predict that IceCure Medical will post -0.28 EPS for the current year.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.